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Filamentous aggregates (fibrils) are regarded as the
final stage in the assembly of amyloidogenic proteins
and are formed in many neurodegenerative diseases.
Accumulation of aggregates occurs as a result of an
imbalance between their formation and removal.
Here we use single-aggregate imaging to show that
large fibrils assembled from full-length tau are sub-
strates of the 26S proteasome holoenzyme, which
fragments them into small aggregates. Interestingly,
although degradation of monomeric tau is not in-
hibited by adenosine 5’-(3-thiotriphosphate) (ATPgS),
fibril fragmentation is predominantly dependent on
the ATPase activity of the proteasome. The protea-
some holoenzyme also targets fibrils assembled
from a-synuclein, suggesting that its fibril-fragment-
ing function may be a general mechanism. The frag-
mented species produced by the proteasome shows
significant toxicity to human cell lines compared with
intact fibrils. Together, our results indicate that the
proteasome holoenzyme possesses a fragmentation
function that disassembles large fibrils into smaller
and more cytotoxic species.
INTRODUCTION
Protein aggregation is often associated with neurodegenerative
disorders and aging-related dementia (Goedert, 2015). Alz-
heimer’s and Parkinson’s diseases are common dementia-like
disorders involving aggregation of the distinct amyloidogenic
proteins tau and a-synuclein (aS), respectively (Iqbal et al.,
2005; Lashuel et al., 2013). The protein tau is suggested to
participate in the assembly and stability of microtubules but
has also been associated with other functions (Wang and Man-
delkow, 2016). aS is able to interact with phospholipids and ves-
icles and believed to be involved in cellular vesicle trafficking and
neurotransmitter release (Bendor et al., 2013). Both tau and aS
are largely intrinsically disordered when not associated with
other proteins (Schwalbe et al., 2014; Theillet et al., 2016).
Amyloidogenic proteins have a propensity to misfold and oli-
gomerize (Soto, 2003). As oligomers grow in size by addition of2140 Cell Reports 26, 2140–2149, February 19, 2019 ª 2019 The Aut
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increased stability take place, eventually resulting in a highly
ordered and filamentous arrangement of aggregates that are
no longer soluble in the physiological environment (Spillantini
and Goedert, 2013). How these aggregates relate to toxicity
leading to cell death and ultimately cause pathological disorders
remains disputed, although distinct types of aggregates have
been found to impede cellular signaling and compromise the
integrity of neuronal functions (Goedert and Spillantini, 2017;
Haass and Selkoe, 2007; Labbadia andMorimoto, 2015; Selkoe,
2004). The size and type of aggregates may also determine
how they are processed by cells and either targeted for degrada-
tion or sequestered at distinct cellular sites (e.g., Woerner et al.,
2016).
Although the formation of aggregates has been researched
extensively, little is known about their removal. Aggregate degra-
dation via both the proteasomal and the lysosomal systems has
been described in the literature (e.g., Wang and Mandelkow,
2012; Webb et al., 2003). Although larger aggregates are
believed to be cleared by lysosomes, removal of smaller oligo-
mers has been attributed to the proteasome (Rubinsztein,
2006). The 26S proteasome holoenzyme is an abundant multisu-
bunit protein complex responsible for the regulation of many key
signaling pathways and general cell homeostasis (Schmidt and
Finley, 2014). This complex consists of a cylindrically shaped
20S core particle (CP) and one or two 19S regulatory particles
(RPs) that cap the CP at either end (Tomko and Hochstrasser,
2013; modeled in Figure S1A). Degradation activity is provided
by several proteases within the interior of the CP, whereas the
RP is responsible for the recognition of ubiquitin (Ub)-modified
substrates, which are subsequently unfolded and translocated
into the CP (Bhattacharyya et al., 2014). Six ATPases arranged
in a hexameric ring are found within the base of the RP, which
couples ATP hydrolysis to substrate unfolding and translocation
through its channel pore. In cells, both tau and aS have been re-
ported to be degraded by the proteasome (Lee et al., 2010; Rott
et al., 2011), whereas aggregates assembled from these proteins
have not been found to be targeted by the proteasome in vitro
(e.g., Iljina et al., 2016; Myeku et al., 2016). It is further possible
that distinct aggregate conformations of sufficient size and sta-
bility may be recognized but not processed by the proteasome
and, thus, inhibit its activity, as suggested for tau, aS, amyloid-
b, and prion protein aggregates (Kristiansen et al., 2007; Myeku
et al., 2016; Tseng et al., 2008; Zhang et al., 2008).hors.
commons.org/licenses/by/4.0/).
Here we use single-aggregate total internal reflection fluores-
cence (TIRF) microscopy to show a previously unidentified
aggregate fragmentation function of the proteasome holoen-
zyme that targets fibrils in an Ub-independent manner. Fibrils
assembled from full-length tau were predominantly fragmented
by the proteasome in an ATP-dependent manner, whereas inhib-
iting the proteolytic activity of the proteasome had a negligible
effect on the fragmentation function. Fragmentation was further
confirmed by transmission electron microscopy (TEM), revealing
a species that resembled amorphous aggregates following
proteasome treatment. This aggregate species was more toxic
to cultured mammalian cells than fibrils, triggering a significant
level of cell death. Our findings were further confirmed using
aS fibrils, suggesting that this fragmenting function is not
restricted to targeting tau fibrils. Together, our findings demon-
strate the ability of the proteasome holoenzyme to disassemble
fibrils, and its activity may be regulated by altering the physiolog-
ical ratio of the holoenzyme to the free proteasomal core and
regulatory particles.
RESULTS
The Proteasome Holoenzyme Degrades Monomeric Tau
To study how filamentous aggregates (fibrils) may be processed
by mammalian proteasomes (Figure S1A), we purified the holo-
enzyme or the RP separately from established HEK293T cells
(Wang and Huang, 2008; STAR Methods). The purity and integ-
rity of the proteasomes were confirmed using SDS-PAGE and
TEM (Figures S1B and S1C). Untagged recombinant full-length
tau (isoform 0N4R, modeled in Figure S2A) containing a single
Pro274Ser substitution was purified to apparent homogeneity
(Figure S2B) and subjected to proteasomal degradation.
The Pro274Ser substitution enhances tau aggregation and is
commonly used in tauopathy models (Allen et al., 2002). Mono-
meric tau was degraded by the holoenzyme, as demonstrated
by the loss of substrate band intensity over time (Figure S2C).
Degradation by the holoenzyme was efficiently inhibited by
50 mM Velcade alone or an inhibitor cocktail (50 mM each of Vel-
cade, MG132, and carfilzomib, all of which target proteasomal
proteases) but not by replacement of ATPwith a slowly hydrolys-
able ATP analog, adenosine 5’-(3-thiotriphosphate) (ATPgS)
(Figure S2C). This result suggests that the degradation of mono-
meric tau is dependent on the proteolytic but not the ATPase-
catalyzed unfolding-translocation activity of the proteasome
and that Velcade is sufficient to fully inhibit proteasomal degra-
dation of tau proteins.
Tau Fibrils Are Fragmented in the Presence of the
Proteasome Holoenzyme
We next tested whether aggregates assembled from tau may
also be targeted by the proteasome holoenzyme. Fibrils assem-
bled from tau could be reproducibly obtained at similar levels
after 24 h of aggregation reaction following established proto-
cols (e.g., Kundel et al., 2018). Aggregated tau samples were
treated with the proteasome or an ATP-containing buffer control
and subsequently mixed with a second solution containing
pentameric formylthiophene acetic acid (pFTAA; Figure 1A), a
fluorophore that emits fluorescence upon binding to amyloidstructures in aggregates (Brelstaff et al., 2015). We further estab-
lished an approach to detect aggregated proteins directly on a
glass coverslip surface (Figure 1B, left). Our approach does not
require prior labeling of tau proteins and permits fluorophores
in solution to reversibly bind the aggregates, prolonging imaging
lifetime. Aggregates were imaged on a custom-built fluores-
cence TIRF microscope (Figure S3A) and analyzed using
custom-written scripts we developed to assess individual aggre-
gate size and fluorescence intensity, which, in turn, reflects the
level of amyloid structures present (Figure S3B; STARMethods).
The size (apparent length) of individual pFTAA-positive aggre-
gates as detected by TIRFwas plotted against their fluorescence
intensity and presented in 2D graphs. The level of amyloid struc-
tures defined in each aggregate increases proportionally with
aggregate size (Figure S3C). Based on the contours of aggre-
gates, we will refer to the large aggregates (length, >1 mm) with
distinct shapes and high amyloid structure content as fibrils
and those with indistinct morphology because of the resolution
(length, <1 mm) as small aggregates (Figure 1B, right;
Figure S3D).
Large fibrils (up to 15 mm in length) assembled from tau pro-
teins could still be detected even after 20 h of incubation in
degradation buffer without the proteasome. These fibrils
constituted about 55% of all aggregates (510 fibril and 419
small aggregate counts; Figure 1C). In comparison, incubation
with the proteasome holoenzyme quantitatively removed tau
fibrils (95 counts, 7% of the total), whereas the level of small
aggregates increased (562 counts; Figure 1D). The standard
deviation (SD) from the mean of the experiments was less
than 20% for both fibrils and small aggregates. Proteasomes
alone did not bind pFTAA and, therefore, could not contribute
to any fluorescence signals detected (Figure S4A). An ATP
regeneration system was added to both the control and pro-
teasome-treated samples to maintain the ATP concentration
during the assay (STAR Methods).
Fibrils Are Targeted by ATP-Dependent Proteasomal
Activity
An equilibrium may potentially exist between fibrils, soluble olig-
omers, and monomers, the last of which could be degraded by
the proteasome and, thus, lead to an equilibrium shift favoring
fibril disassembly. To validate that fibrils were being targeted
by the proteasome, we repeated the experiments in Figures 1C
and 1D after soluble tau monomers and oligomers were
separated from aggregated proteins by centrifugation (STAR
Methods). After removing the supernatant, the pellet containing
the fibrils was resuspended with fresh buffer. Following incuba-
tion in the buffer control for 20 h, fibrils up to 15 mm in length
(407 counts or 54% of the total; Figure 2A) were still detected
at a similar level as in Figure 1C. As expected, incubation with
the holoenzyme led to fibril fragmentation, resulting in a drop
in the level of fibrils (155 counts, 12% of total) and an increase
in the number of small aggregates (891 counts, Figure 2b). These
results indicate the presence of a proteasomal function that
fragments tau fibrils. Plausibly, the proteasome may fragment
a single fibril into many small aggregates, at least some of which
may be detected by TIRF imaging. The increase in the level of
small aggregates here is in agreement with Figure 1 andCell Reports 26, 2140–2149, February 19, 2019 2141
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Figure 1. Imaging Fibrils with a Fluorescence TIRF Microscope
(A) Recombinant full-length tau was aggregated for 24 h, and aliquots were taken andmixed with the proteasome in an ATP-containing proteasome buffer or with
the buffer only as a control. After 0.5 h (starting reference) and 20 h of incubation, each reaction was diluted in an imaging buffer containing pFTAA. The chemical
structure of pFTAA, which binds amyloid structures, is shown.
(B) Samples were placed on a glass coverslip, excited with a 488 nm laser, and imaged on a custom-built TIRF microscope (see also Figure S3). A typical fibril
(length, >1 mm) and diffraction-limited small aggregate (length, <1 mm) are shown. The scale bar represents 1 mm.
(C andD) A large amount of fibrils remained present after incubation with the buffer alone (C), whereas treatment with the proteasome holoenzyme resulted in loss
of fibrils and an increase in small aggregate count (D; depicted next to the 2Dplot). The length of aggregates is plotted against the fluorescence intensity of pFTAA;
the frequency is color-coded in the 2D plots. A processed image from each reaction is shown below the respective plots. The scale bars represent 10 mm.
Results of three biological repeats (n = 3) performed independently using different protein preparations of tau and proteasomewere combined into each plot. The
SD between repeats was less than 20% in our TIRF experiments.suggests that fibrils may have been fragmented into smaller spe-
cies of no more than 1 mm in size. We further addressed the pos-
sibility of contamination by canonical chaperones that may be
responsible for fibril fragmentation; the fragmenting activity
was unaffected by inhibitors of heat shock protein (HSP) 70,
HSP90, or VCP, also known as p97 (Figures S4B–S4E). There-2142 Cell Reports 26, 2140–2149, February 19, 2019fore, the loss of fibrils and the increase in small aggregates
appear to be results of proteasomal action.
To gain insights into the proteasomal mechanisms respon-
sible for this fibril-fragmenting function, we repeated the
same assay using holoenzymes pre-treated with either Velcade
or ATPgS. Fragmentation was largely observed (83 counts of
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Figure 2. Fragmentation of Fibrils in the Absence of Soluble Tau Proteins
(A and B) Aggregated tau samples were centrifuged. The pellet was resuspended in fresh proteasome buffer followed by incubation with (A) buffer control or (B)
the proteasome holoenzyme for 20 h and subsequently imaged and presented as described in Figure 1.
(C and D) Proteasome holoenzymes pre-treated with (C) Velcade (proteasomeVelcade) or (D) ATPgS (proteasomeATPgS) were subsequently incubated with
aggregated tau as in (B).
(E) Instead of the holoenzyme, fibrils were also incubated with regulatory particles (RPs) and analyzed as above.
Combined results of three independent experiments (n = 3) are shown.remaining fibrils), even after inhibition of proteolytic activity
(proteasomeVelcade; Figure 2D), further excluding the scenario
that proteolytic degradation of tau proteins mediates the loss
of fibrils. The number of small aggregates (290 counts) re-
mained at a similar level as the control in Figure 2A. In contrast,
compromising the ATP-dependent activity (proteasomeATPgS)
impeded the fragmenting function, leaving the fibril level largely
unchanged (660 counts; Figure 2E). The lower ratio of fibrils
(30%) when incubated with proteasomeATPgS is due to theapparent level of small aggregates detected (1,341 counts).
These observations together imply that the fragmentation of
fibrils relies predominantly on the ATPase activity of the
proteasome.
Integrity of Proteasome Holoenzyme Required for Fibril
Fragmentation
Because fibril fragmentation was mainly dependent on proteaso-
mal ATPase activity, we attempted to independently verify ourCell Reports 26, 2140–2149, February 19, 2019 2143
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Figure 3. Aggregation of Tau in the Presence of Proteasome Holoenzymes
(A and B) Monomeric tau proteins at 2 mM final concentration were mixed with proteasome buffer and imaged after (A) 0.5 h or (B) 24 h, showing a substantial
increase in both fibril and small aggregate levels.
(C–E) Aggregation of tau in the presence of 40 nM final concentration of (C) untreated, (D) Velcade-treated, and (E) ATPgS-treated proteasome holoenzyme,
measured after 24 h of incubation.
Each plot contains the cumulative data from three independent measurements (n = 3).observations using purified freeRPs.Unexpectedly, no significant
fibril fragmentation was detected in the presence of RP (Fig-
ure 2E), and the level of fibrils (619 counts or 40% of the total) re-
mained largely similar to Figure 2A. This result suggests that the
integrity of the proteasome holoenzyme may be required to
couple functions that are required for efficient fibril fragmentation.
Distinct Activities of Proteasome Holoenzyme Prevent
Tau Aggregation
Although the fibril-fragmenting function of proteasome holoen-
zymes may be relevant to target aggregates that are already
assembled (e.g., in a scenario when aggregates enter the host
cell from the extracellular environment; Ait-Bouziad et al., 2017;
Evans et al., 2018; Takahashi et al., 2015), the proteasomalmech-
anisms that are involved in clearing cytosolic misfolded proteins
to prevent intracellular aggregate formation may be distinct
from its fibril-fragmenting function. To further validate the obser-
vations in Figure 2 andmimic a physiological scenario where pro-
teasomes are already present during the aggregation process, we
attempted to assemble tau aggregates in the presence the holo-
enzyme. Without the proteasome, fibrils emerged 0.5 h after ag-
gregation start (Figure 3A), and a significant number of fibrils
(994 counts or 34% of the total; Figure 3B) was observed after
24 h of reaction. In comparison, aggregation in the presence of
holoenzymes restricted the ratio of fibrils (13%, 141 counts)
assembled after 24 h (Figure 3C). Selectively inhibiting the proteo-
lytic or ATPase activities of the proteasome partly restored the
fibril level (704 and 978 counts, respectively; Figures 3D and
3E), suggesting that both activities are involved in impeding fibril
formation from protein monomers. It therefore appears that the
proteasomal mechanisms observed here, which are involved in2144 Cell Reports 26, 2140–2149, February 19, 2019reducing tau aggregation, are distinct from the fibril-fragmenting
function in Figure 2, where the proteasomes were introduced to
pre-assembled fibrils. Interestingly, proteasomeATPgS incubation
enabled both more and large fibrils (over 10 mm) to form
compared with proteasomeVelcade, consistent with a central role
of ATPase activity in fibril disassembly.
TEM Detects Amorphous Structures following
Proteasome Treatment
The fragmentation function of the proteasome in Figure 2 was
further independently validated using TEM. Fibrils in the absence
of the proteasome remained intact after incubation with a buffer
control (Figure 4A). These fibrils were lost following proteasome
treatment, and only unstructured clusters of proteins resembling
amorphous aggregates were detected (Figure 4B), which were
not present without proteasome treatment. Because of the
intrinsic properties of uranyl acetate, which stains aggregates
as well as proteasomes, we repeated these experiments using
immunogold labeling with an anti-tau antibody to confirm the
presence of tau proteins within these amorphous structures.
This approach selectively labeled fibrils in the control sample
(Figure 4C) as well as the fragmented species of amorphous
structures after proteasome treatment (Figure 4D). These data
indicate that tau-containing amorphous structures are formed
following fibril fragmentation by the proteasome. Because the di-
mensions of these amorphous aggregates are mostly less than
1 mm, they are likely to have contributed to the small aggregates
observed in Figure 2.
Intact proteasome holoenzymes could be detected under
TEM after overnight incubation with the sample (Figure 4B).
This suggested that aggregated tau proteins did not affect the
Figure 4. Disordered Aggregates of Amor-
phous Structures Detected by TEM after
Fragmentation by the Proteasome
(A and B) Aggregated tau samples prepared as in
Figure 2 were incubated with (A) an ATP-containing
buffer or (B) proteasome holoenzyme for 20 h,
stained with uranyl acetate, and imaged by TEM.
Arrows indicate typical aggregated structures.
(C and D) Aggregated samples incubated with (C)
the buffer control or (D) the proteasome were
immunolabeled with an anti-tau antibody, stained
with uranyl acetate, and imaged by TEM.
The scale bars represent 100 nm. Representative
images are shown of at least three independent
repeats.integrity of the holoenzyme. Consistently, we detected no quan-
titative inhibition of the proteasomal peptidase activity against a
model substrate, suc-Leu-Leu-Val-Tyr-7-amino-4-methylcou-
marin (LLVY-AMC), in the presence of fibrils or by a heparin-con-
taining aggregation buffer (Figure S5A), and incubating fibrils
with the active proteasome holoenzyme for 20 h did not affect
its ability to hydrolyze ATP (Figure S5B). Although it may be
possible that other proteasomal functions, such as Ub-depen-
dent degradation, may be impaired as a result of prolonged
interaction with aggregated tau proteins, any such inhibitory ef-
fect would not affect interpretation of our fragmentation data.
Fibril Fragmentation May Increase Cell Lysis
Aggregates assembled from amyloidogenic proteins have been
suggested to trigger cell stress and cytotoxicity; for example, by
disrupting lipid bilayers (Flagmeier et al., 2017). We hypothesized
that the fibril-fragmenting function of the proteasome holoenzyme
that resulted in a higher number of small aggregates would also
lead to increased cytotoxicity, manifested through cell death
(referred to as ‘‘cytotoxicity’’ hereafter). To assess the cytotoxicity
associated with fibril fragmentation, we incubated mammalian
cells with untreated fibril samples or fragmented species and
measured cell viability after 24 h. Viability was monitored using
an established assay based on the release of cytosolic lactate de-
hydrogenase (LDH) into the extracellular medium upon lysis. This
assay therefore reports on the toxicity of the aggregate species
added to the extracellular environment. No lysis was detected
after incubation with fibrils, indicating that the viability of the cells
was not affected (Figure 5A, column 1 from the left). In contrast,
cells incubated with the fragmented species showed a substan-
tially higher level of cell lysis (Figure 5A, column 2). The reduced
cell viability was not caused by the buffer or the proteasomeCell Repoalone, neither of which affected cell lysis
(Figure 5A, columns 3 and 4). In compari-
son, fibrils treated with free RP alone did
not show a significant level of cell lysis
either (Figure 5A, columns 5 and 6), in
agreement with our in vitro data in
Figure 2E.
Because the total number of aggre-
gates increases after proteasome treat-
ment, we addressed whether a higherconcentration of fibrils would also lead to increased cell lysis.
Cells incubated with fibrils alone at 1-, 10-, or 100-fold higher
concentration than in Figure 5A did not cause any detectable
cell lysis compared with the buffer or the tau monomer control
(Figure 5B, columns 1–6). We further questioned whether any
cytotoxic species might have escaped our detection during the
centrifugation procedure, which separated insoluble fibrils from
monomers and soluble aggregates. Neither the supernatant
nor the pellet samples separated by centrifugation resulted in
cell lysis (Figure 5B, columns 7 and 8). A positive control contain-
ing fibrils fragmented by sonication resulted in a high level of cell
lysis (Figure 5B, column 9), consistent with Figure 5A. Together,
these results indicate that the fibril-fragmenting function of the
proteasome may have a negative effect on cell viability.
Conserved Disassembly Action of aS Fibrils by the 26S
Proteasome
To test whether the fibril-fragmenting function may also be pro-
miscuous and target other amyloidogenic proteins, we assem-
bled fibrils from recombinant wild-type aS following previously
established protocols (e.g., Cremades et al., 2012). Purified
monomeric aS is a substrate of the proteasome holoenzyme,
and like tau, its degradation is also dependent on the proteolytic
but not the ATPase activity of the holoenzyme (Figure S6). Fibrils
assembled from aS could be reproducibly detected (1,413 counts
or 28% of the total) under the TIRF microscope after 20 h of incu-
bation with the buffer control (Figure 6A). These fibrils were frag-
mented by the proteasome holoenzyme, resulting in a decrease in
the number of fibrils (1,081 counts or 9%; Figure 6B). The lower
ratio of fibrils is due to a substantial increase in the number of
small aggregates (from 3,682 to 10,864 counts) following protea-
some treatment. When untreated or proteasome-treated fibrilsrts 26, 2140–2149, February 19, 2019 2145
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Figure 5. Fragmented Species Trigger Cell Lysis
(A) A lactate dehydrogenase (LDH) assay was used to detect lysis of HEK293 cells after incubation with either intact aggregated tau (column 1), the
fragmented species (column 2), the buffer alone (column 3), or proteasome holoenzyme alone (column 4). Cells were tested for levels of lysis
after incubation with fibrils treated with free RP (column 5) or with free RP alone as a control (column 6).
(B) Aggregation buffers and tau fibrils are not toxic to cells. Monomers (column 1) or fibrils (column 2–4) at 1-, 10-, and 100-fold (103 and 1003) of the in-
cubation concentration in (A) were incubated with the cells. Several controls including sodium chloride-sodium phosphate-EDTA (SSPE) buffer alone (column
5), SSPE buffer containing heparin (column 6), the pellet (containing tau fibrils, column 7), or the supernatant fraction (containing soluble aggregates and
monomers, column 8) after centrifugation (STAR Methods) were also tested for cell lysis. As a positive control (column 9), fibrils were sonicated briefly and
centrifuged to separate insoluble fibrils so that the supernatant could be added to cells at the same calculated concentration.
Error bars represent SD of measurements from the mean of three independent experiments (n = 3).were stained with uranyl acetate and imaged by TEM, we de-
tected smaller aggregate species of distinct structures following
fragmentation (Figures 6C and 6D). These species were not
amorphous and may account for the higher fluorescence signal
detected by TIRF imaging after fragmentation of aS fibrils. Similar
to tau, fragmented aS entities were also significantlymore toxic to
cells (28% cell lysis) than intact fibrils (3% lysis; Figure 6E).
Overall, the conservation of the fragmenting function against
both tau and aS fibrils suggests that the proteasome holoenzyme
may serve as a promiscuous fibril fragmentase able to indiscrim-
inately target fibril structures in general.
DISCUSSION
In this study we identified a fibril-fragmenting function of the
proteasome holoenzyme that targets fibrils assembled from
tau and aS proteins in an ATP-dependent manner and does
not require its proteolytic activity. This fibril-targeting function
makes the proteasome holoenzyme a structurally and function-
ally distinct fibril-fragmenting enzyme compared with other2146 Cell Reports 26, 2140–2149, February 19, 2019aggregate-targeting enzymes in the existing family of disaggre-
gases, such as Hsp104, which reverses aggregation of prion
proteins (Shorter and Lindquist, 2004), and several HSP70-con-
taining disaggregase complexes (Gao et al., 2015; Nillegoda
et al., 2015), one of which has been reported to target aS aggre-
gates (Gao et al., 2015). We further showed that this fragmenting
function of the proteasome on pre-assembled fibrils is distinct to
the proteasomal actions involved in preventing aggregation of
misfolded proteins, which requires both the ATPase and proteo-
lytic activities.
The proteasome has canonically been described to target olig-
omers and smaller aggregates in solution, whereas degradation
of larger fibrils is performed by the lysosomal system (Rubinsz-
tein, 2006). In this study, we provide evidence that amends this
view, showing a previously unidentified ability of proteasome
holoenzymes with molecular dimensions of 15 3 40 nm
(PDB: 5GJR) to fragment fibrils up to 20 mm in length indepen-
dently of Ub modification. The recent molecular structure of tau
filaments derived from an Alzheimer’s patient reveals extensive
b sheet stacking of tau monomers, suggesting a high degree of
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Figure 6. Proteasome Fragments aS Fibrils into Cytotoxic Species
(A and B) Aggregates were assembled from aSmonomers for 24 h and subsequently incubated with (A) an ATP-containing buffer or (B) proteasome holoenzyme
for 20 h and presented in 2D plots as in Figure 2. Combined data of three independent repeats are shown (n = 3).
(C and D) The assay was repeated with untreated (C) or proteasome-treated (D) aggregated aS for TEM imaging. Arrows indicate typical aggregated structures.
The scale bars represent 100 nm.
(E) HEK293 cells incubated with untreated (column 1) and proteasome-treated (column 2) samples of aggregated aS proteins, the buffer (column 3), or the
proteasome alone (column 4) were tested for cytotoxicity using the LDH assay as in Figure 5A. Mean values are shown, with error bars representing SD.
All experiments were independently repeated at least three times (n = 3) using fresh aS and proteasome preparations.stability (Fitzpatrick et al., 2017). Our results therefore imply a
remarkable ability of the proteasome to target and fragment
stable structures several orders of magnitude larger.
Early in vitro studies have suggested an ATP-dependent
chaperone-like function of the RPwith affinity to denatured pro-
tein structures without Ub modification (Braun et al., 1999).
Recent in vivo studies have further found proteasomal recruit-
ment to aggresomes in HEK cells (Hao et al., 2013; Nanduri
et al., 2015) and to poly-Gly-Ala repeat (poly-GA) aggregates
in neurons (Guo et al., 2018), hinting at plausible proteasome
involvement in targeting aggregates. Our findings in this
study provide additional evidence suggesting that the ATP-
dependent fibril-fragmenting function may also be driven by
the unfolding or chaperone-like mechanism, perhaps when
substrates cannot be a proteolytic target susceptible to direct
degradation.
The current study has focused on the fibril-fragmenting func-
tion of proteasome holoenzymes on unmodified recombinant
tau and aS. In physiological settings, extensive posttranslational
modifications have been identified on tau that affect its aggrega-
tion properties or are associated with pathological conse-
quences (Morris et al., 2015; Thomas et al., 2012). Similar effects
of various posttranslational modifications have also been
reported for aS (Barrett and Timothy Greenamyre, 2015; Hase-
gawa et al., 2002; Tofaris et al., 2003). The range of aggregate
species found in vivo that may be targeted by the fibril-fragmenting function of the proteasome or, alternatively, those
that are resistant to or inhibitory of this function remain to be
studied. Identification of the proteasome holoenzyme with a
fibril-fragmenting activity, in addition to its canonical role as a
mediator of the degradation of misfolded proteins, could be an
interesting amendment to the repertoire of cellular instruments
targeting protein aggregation.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-tau clone 1E1/A6 Millipore Cat#05-804; RRID:AB_11211556
Rabbit monoclonal anti-aS clone MJFR1 Abcam Cat#ab138501; RRID:AB_2537217
Chemicals, Peptides, and Recombinant Proteins
pFTAA Brelstaff et al., 2015 Kind gift from Michel Goedert
Heparin Fisher Scientific Cat#BP2524-50
ATP Sigma-Aldrich Cat#A1388-5MG
Velcade Generon Cat#HY-10227-10mg
MG132 Generon Cat#10012628-5 mg-CAY
Carfilzomib Generon Cat#HY-10455-10mg
ATPgS Sigma-Aldrich Cat#A1388-5MG
VER155008 Sigma-Aldrich Cat#SML0271-5MG
Geldanamycin Sigma-Aldrich Cat#SML1278-1ML
NMS-873 Sigma-Aldrich Cat#SML1128-5MG
Critical Commercial Assays
Malachite Green assay Abcam Cat#ab65622
LLVY-AMC Enzo Lifesciences Cat#BML-P802-0005
LDH assay Thermo Fisher Cat#88953
Experimental Models: Cell Lines
HEK293T cells stably expressing Rpn11-His6-TEV-biotin Kind gift from Lan Huang
Recombinant DNA
pRK172 vector expressing recombinant tau(0N4R) with P301S mutation Kind gift from Michel Goedert
pT7-7 vector expressing recombinant asynWT Addgene Cat#36046
Software and Algorithms
MATLAB MathWorks Version 2016b
ImageJ National Institute of Health, USA Version 1.0
Other
SSPE buffer Thermo Fisher Cat#AM9770
PBS buffer Fisher Scientific Cat#BP399500CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yu Ye
(yy308@cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Plasmids and Cell Lines
All plasmids and cell lines used in this study are listed under Key Resources Table. Plasmids expressing untagged full-length tau
(isoform 0N4R) containing a single Pro274Ser substitution or wild-type a-synuclein (aS) in pT7-7 vectors were transformed into
BL21 cells. BL21 (DE3) pLysS E. coli cells were grown at 37C in LB media containing 100 mg/ml ampicillin under shaking conditions
and protein expression was induced at an O.D. of 1.0 using 1 mM IPTG for 4 hr at 20C.
HEK293T cells (female) stably expressing a fusion construct coding for Rpn11-His6-TEV-biotin were used for proteasome purifi-
cation. The cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Sigma) and 1%
penicillin/streptomycin (Thermo Fisher Scientific). A dedicated incubator at 37C was used to incubate the cells in an atmosphere
of 5% CO2 in air. Monolayers of cells at > 90% confluence were collected using a cell scraper for subsequent purification steps.e1 Cell Reports 26, 2140–2149.e1–e3, February 19, 2019
METHODS DETAILS
Protein purification
BL21 cells expressing recombinant proteins were collected by centrifugation at 4000 3 g and then resuspended in ice-cold Lysis
buffer (50 mM MES pH 6.5, 2.5 mM TCEP, 1 mM AEBSF). Lysis of cells was carried out by sonication and the lysate was cleared
by centrifugation at 230003 g for 30 min at 4C. The pH of the cleared lysate containing tau was gradually reduced to 4.5 and incu-
bated on ice for 10min before repeating the centrifugation at 230003 g to clear the lysate of precipitants. The supernatant containing
tau was filtered and subsequently loaded onto a ResourceS ion exchange column (GE Healthcare) and eluted with a linear NaCl
gradient. Eluted fractions containing tau were identified by SDS-PAGE and loaded onto Superdex 16/60 (GE Healthcare) gel filtration
column for a final purification step (Figure S2B). For aS purification, the cleared lysate was incubated in boiling water for 15 min
followed by another centrifugation procedure at 230003 g for 30 min at 4C. The aS supernatant was then loaded onto a ResourceQ
anion exchange column and elutedwith a linear NaCl gradient. Fractions containing aSwere loaded onto Superdex 16/60. The eluted
fractions from gel filtration were examined by SDS-PAGE and fractions judged pure were concentrated and flash-frozen.
Purification of mammalian proteasome holoenzymes or the free regulatory particle (RP) was carried out as described elsewhere
(Wang and Huang, 2008). Briefly, HEK293T (female) cells were resuspended in Proteasome buffer (50mM Tris [pH7.5], 5 mM ATP,
5 mM MgCl2) and lysed using a dounce homogenizer. Cell lysate was cleared by centrifugation at 1500 3 g for 10 min and the
supernatant was incubated with 2 mL NeutrAvidin beads overnight at 4C. On the next day, beads were washed with TB buffer
(50mM Tris [pH7.5], 5 mM ATP, 5 mM MgCl2, 10% glycerol) and bound holoenzymes were eluted after 3 hr of incubation with 6 ml
TEV protease (Sigma) at 30C. For RP purification, the beads were first washed with TBN buffer (TB buffer containing 800 mM
NaCl) to release the CP from the bound RP and then with additional TB buffer prior to the TEV protease cleavage step. Subsequent
purification steps were the same as for the holoenzyme.
Aggregation assays
Aggregation reactions for tau were set up at 2 mM final concentration in SSPE buffer (10 mM Na3PO4 (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 0.02% Sodium Azide) in the presence of 2 mM heparin (5000 Da, Fisher Scientific) at 37C(Kundel et al., 2018). For aS aggre-
gation, protein was diluted to 70 mM final concentration in PBS buffer (Fisher Scientific) containing 0.02% Sodium Azide and per-
formed under shaking conditions at 37C(Cremades et al., 2012). Both tau and aS were aggregated for 24 hr and used immediately
for subsequent reactions. All buffers used in our assays were pre-filtered with 0.02 mm filters.
Aggregation reactions in Figure 3 contained 2 mM and 40 nM final concentration of tau and proteasome holoenzyme, respectively,
in the Proteasome buffer with an ATP regeneration system (20 mMCreatine phosphate and 5 mMCreatine kinase final concentration)
and initiated with 2 mM heparin at 37C as described above.
Proteasome assays
Aliquots were removed from aggregation reactions after 24 hr and incubated with the proteasome. The final reactions contained 8 ml
of 200 nM proteasome, 8 ml of the aggregated tau or aS substrate, 5 ml of 103 Proteasome buffer, 2.5 ml of a 203 ATP regeneration
system (2 M Creatine phosphate and 100 mMCreatine kinase) and ddH2O to make up 50 ml final reaction volume. The reactions were
performed at 25C to avoid further aggregation. After 0.5 hr (used as a reference) and 20 hr of incubation, 1 ml aliquot was removed
from each reaction and serially diluted 50-fold in PBS buffer containing 30 nMpFTAA for TIRF imaging (see below). For experiments in
Figures 2, 3, 4, 5, and 6, prior to the proteasome treatment step, aggregated samples were centrifuged on a benchtop centrifuge at
maximum velocity for 30 min. The supernatant was subsequently removed and resuspended with an equal volume of Proteasome
buffer before incubation with the proteasome. In control reactions, the proteasome was replaced with an equal volume of the
Proteasome buffer. The distinct catalytic activities of the proteasome were inhibited by pre-incubation with Velcade or ATPgS for
5 min in room temperature before mixing with the substrate. The final concentrations of Velcade and ATPgS used were 50 mM
and 9 mM, respectively. No ATP was added to the buffer in reactions containing ATPgS. Proteasomes pre-treated with
VER155008, Geldanamycin and NMS-873 were prepared the same way as Velcade and used at 50 mM final concentration.
LLVY-AMC and Malachite Green assays
LLVY-AMC (Enzo Lifesciences) was used at 1 mM final concentration and incubated either with 40 nM final concentration of protea-
some alone, with the proteasome in presence of 320 nM heparin or with 320 nM aggregated tau proteins. The sample was excited
at 340 nm and emission detected over time on a fluorimeter (Cary Eclipse) at 440 nm. ATPase kit containing the Malachite Green
assay was purchased from Abcam (ab65622). For experiments in Figure S5B, 40 mL Proteasome assays set up as described above
were mixed with 6 mL of the malachite green reagent and incubated for 15 min before measuring the O.D. at 650 nm on a microplate
reader. Free phosphates were used to establish a linear standard curve to calculate phosphate concentrations from colorimetric
readings.
Degradation assays of protein monomers
Degradation assays of protein monomers were set up mixing 8 ml tau or aS at 2 mM or 70 mM, respectively, with 8 ml of 200 nM pro-
teasome and H2O to make a final 50 ml reaction volume. At indicated time points, 6 ml of samples were removed and quenched withCell Reports 26, 2140–2149.e1–e3, February 19, 2019 e2
6 ml LDS buffer and stored by flash-freezing for subsequent protein gel electrophoresis. Protein samples were separated by 4%–12%
Bolt SDS-PAGE gels (Invitrogen) and transferred to PVDF membranes using Trans-blot Turbo (Biorad) semi-dry transfer system as
per manufacturer’s protocol. Membranes were incubated with primary antibodies against tau (1E1/A6, Millipore) or aS (MJFR1,
Abcam) overnight. Protein bands were detected using secondary anti-mouse or anti-rabbit antibodies tagged with Alexa647 (Invitro-
gen) and scanned on a Typhoon Imager.
TIRF imaging
Prior to imaging, glass coverslips (0.13 mm thickness, VWR International) were cleaned with an argon plasma (PDC-002, Harrick
Plasma) for 1 hr. A multi-well chambered coverslip (Sigma-Aldrich, GBL103350-20EA) was adhered to each glass coverslip to allow
for imaging of multiple samples. For the imaging of aS samples, each well was coated with 0.01% poly-L-lysine (MW 150,000-
300,000, Sigma-Aldrich) for 15 minutes, then washed three times with sterile-filtered PBS buffer. For tau samples, the glass cover-
slips were untreated. The imaging concentrations for tau and aS were 20 nM and 100 nM, respectively, of the calculated monomer
concentration. Samples were imaged in the presence of 30 nM pFTAA dye (kind gift from Michel Goedert) in PBS buffer, using a
home-built total internal reflection fluorescence (TIRF) microscope as shown in Figure S3A.
TEM imaging
Samples for TEM imaging were prepared as for TIRF imaging and applied onto a carbon-coated 400 mesh copper grid (Agar Scien-
tific). Proteasome samples were applied at 100 nM final concentration. Samples were stained with 2% (w/v) uranyl acetate for 1 min
and subsequently washed twice with ddH2O. TEM images were acquired using Tecnai G2 microscope (13218, EDAX, AMETEK)
operating at an excitation voltage of 200 kV.
Cytotoxicity assays
Fibrils treated with either the Proteasome buffer or with the proteasome holoenzyme (described in the Proteasome Assays section)
were added in triplicate to confluent HEK293A cells grown in 96-well plates. The cells were subsequently incubated at 37C for 24 hr
in 200 ml final media volume, from which 100 ml was removed for LDH assay (Thermo Fisher). We followed manufacturer’s protocols
and added 100 ml of the supplied ReactionMixture, which contains the substrate for LDH activity detection, to themedia. After 30min,
the reactions were quenched with the Stop Buffer (supplied with the kit) and the absorbance at 480 nm was measured on a plate
reader. Lysis media supplied by the manufacturer was then added to each well to establish the maximum level of cell lysis. Assays
were repeated at least three times using a new protein preparation each time. Both Velcade and ATPgS alone were found to be toxic
to cells when added to the cells at the concentration used for proteasome inhibition, as significant levels of cell lysis was observed.
QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis and statistics
Images were recorded for 100 frames with 50 ms exposure time. For each sample, 9 fields of view were typically acquired and then
analyzed. These raw images collected by the TIRF microscope (see Figure S3) were analyzed to count the total number of fibrils and
aggregates, their size and fluorescence intensity. The number of fibrils and aggregates counted was then directly compared between
different experiments.
Individual image datawere averaged over all the frames by the average intensity projection at z axis using ImageJ (National Institute
of Health, USA) and then subjected to image processing. A custom-written MATLAB script (MathWorks) was used to analyze the
averaged images. Individual images were first top-hat and bpass filtered to remove the camera noise and partitioned into a fore-
ground and a background. To identify particles, the foreground was blurred using a 2DGaussian filter with a threshold applied based
on the original pixel intensity with a criterion of 2% intensity above the background, and then established boundaries for individual
particles. The particle length was measured by thinning boundaries of individual particles and thus calculated with an image pixel
size of 235 nm for our TIRF setup. To eliminate the background effect in intensity calculation, signal-to-background ratio (SBR)
was introduced to correct pixel intensity, where each pixel’s SBR is defined as:
SBR=
Intensity above the background
Background
For a given particle, its corrected intensity is the sum of each pixel’s SBR values within its boundary. We typically detect over 800
fibrils and aggregates for each experiment. Increasing the number of images does not affect the ratio between fibrils and aggregates,
indicating that our sample size was sufficiently large to be representative.
Statistical analysis
Mean and stand deviation from three biological repeats (n = 3) of each assay are shown in Figure 5 and Figure 6E. For TIRF measure-
ments in Figure 2 and Figure 3, results of three biological repeats (n = 3) performed independently using different protein preparations
of tau and proteasome were combined into each plot. The standard deviation between repeats was less than 20%.e3 Cell Reports 26, 2140–2149.e1–e3, February 19, 2019
